T2 Capital Management

T2 Biosystems is a commercial-stage medical diagnostics company focused on the rapid detection of sepsis-causing pathogens and antibiotic resistance genes. The company's proprietary T2 Magnetic Resonance (T2MR) technology enables the identification of pathogens directly from whole blood, bypassing the need for time-consuming blood cultures and delivering results in hours rather than days. Its core product suite includes the T2Dx Instrument and various diagnostic panels, such as the T2Candida, T2Bacteria, and T2Resistance panels. By providing faster targeted treatment options, T2 Biosystems aims to improve patient outcomes, reduce hospital stays, and lower the overall cost of care in critical healthcare settings.